Approval · Notice of Compliance 930 · 2003
GEN-GABAPENTIN: Notice of Compliance 930
Issued November 3, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 930
- Date
- November 3, 2003
- Company
- Genpharm Inc.Etobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GEN-GABAPENTIN | 02248259 | Cancelled Post Market |
| GEN-GABAPENTIN | 02248260 | Cancelled Post Market |
| GEN-GABAPENTIN | 02248261 | Cancelled Post Market |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP